Junshi/Lilly Dual Antibody Treatment Approved in US to Treat COVID-19
February 10, 2021 at 06:12 AM EST
Junshi Biosciences and Eli Lilly announced their dual mAb treatment was approved in the US to treat COVID-19 under emergency use rules. In a US Phase II/III trial, a combination of Junshi's etesevimab (JS016) and Lilly's bamlanivimab (LY-CoV555) reduced the risk of COVID-19 hospitalizations and death by 70% in newly diagnosed patients. It is indicated for patients with mild to moderate COVID-19 aged 12 and older who are at high risk for progressing to severe COVID-19 and/or hospitalization. More details.... Stock Symbols: (HK: 1877; SHA: 688180) (NYSE: LLY) Share this with colleagues: // //